PatientsVille.com Logo


Etoposid Medical Research Studies

Up-to-date List of Etoposid Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Etoposid Medical Research Studies

Rank Status Study
1 Recruiting Bendamustine in Combination With Ofatumumab, Carboplatin and Etoposide for Refractory or Relapsed Aggressive B-Cell Lymphomas
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Bendamustine;   Drug: Ofatumumab;   Drug: Carboplatin;   Drug: Etoposide;   Procedure: CT Scan;   Procedure: PET Scan;   Genetic: Stem Cell Transplant (STC)
Outcome Measures: Phase I: Maximum-Tolerated Dose of Bendamustine in Combination with Ofatumumab, Carboplatin and Etoposide (BOCE);   Phase II: Overall Frequency of Response with Combination of Bendamustine, Ofatumumab, Carboplatin, and Etoposide;   Phase I: Overall Frequency of Response;   Phase II: Complete Response (CR) and Partial Response (PR) Rate;   Phase II: Progression-Free Survival;   Phase II: Overall Survival;   Phase II: Proportion of Patients Who Are Able to Undergo Stem Cell Transplant (SCT);   Phase II: Safety and Tolerability of the Combination of Bendamustine, Ofatumumab, Carboplatin, and Etoposide
2 Recruiting Trial in Extensive-Disease Small Cell Lung Cancer (ED-SCLC) Subjects Comparing Ipilimumab Plus Etoposide and Platinum Therapy to Etoposide and Platinum Therapy Alone
Condition: Small Cell Lung Carcinoma
Interventions: Biological: Ipilimumab;   Biological: Placebo matching Ipilimumab;   Drug: Etoposide;   Drug: Cisplatin;   Drug: Carboplatin
Outcome Measures: Overall Survival;   Overall Survival (OS) of subjects who received blinded study therapy;   Immune-related Progression Free Survival (irPFS);   Progression Free Survival [using Modified World Health Organization (mWHO) criteria];   Best Overall Response Rate by mWHO (BORR);   Duration of Response by mWHO (DoR)
3 Recruiting Randomized Study of Cisplatin-Etoposide Versus an Etoposide Regimen Without Cisplatin in Extensive Small-Cell Lung Cancer
Condition: Small Cell Lung Carcinoma, Extensive Disease
Interventions: Drug: Cisplatin + Etoposide;   Drug: Epirubicin + ifosfamide + Etoposide
Outcome Measures: Survival;   Response rate;   Toxicity
4 Recruiting Bendamustine Hydrochloride, Clofarabine, and Etoposide in Treating Younger Patients With Relapsed or Refractory Hematologic Malignancies
Conditions: Hodgkin Lymphoma;   Non-Hodgkin Lymphoma;   Acute Leukemia
Interventions: Drug: Bendamustine;   Drug: Clofarabine;   Drug: Etoposide;   Drug: Etoposide phosphate;   Drug: Dexamethasone
Outcome Measures: Maximum tolerated dose;   Dose limiting toxicities;   Event free survival;   Proportion of leukemia participants with positive minimal residual disease;   Plasma concentration of bendamustine
5 Recruiting Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients < 21 Years at Diagnosis With Refractory Solid Tumors
Conditions: Solid Tumors;   Relapsed/Refractory Sarcomas
Intervention: Drug: Vorinostat and Etoposide
Outcome Measures: To establish the Dose Limiting Toxicity (DLT);   To establish the Maximum Tolerated Dose (MTD);   To establish the efficacy (CR (Complete Response) + PR (Partial Response) rate);   To evaluate the efficacy (CR (complete response) + PR (partial response) rate);   To evaluate the biologic effects using Histone Acetylation, Gene Expression Profiling, and Histone Phosphorylation Profiling.
6 Recruiting Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-Small Cell Lung Cancer
Conditions: Extensive Stage Small Cell Lung Cancer;   Large Cell Lung Cancer;   Metastatic Carcinoma of Unknown Primary;   Neuroendocrine Carcinoma;   Newly Diagnosed Carcinoma of Unknown Primary;   Stage IV Non-small Cell Lung Cancer
Interventions: Drug: veliparib;   Other: placebo;   Drug: Etoposide;   Drug: cisplatin;   Other: laboratory biomarker analysis;   Other: questionnaire administration;   Other: quality-of-life assessment
Outcome Measures: Maximum-tolerated dose of veliparib based on the incidence of dose-limiting toxicity as assessed by the Common Terminology Criteria for Adverse Events version 4.0 (Phase I);   PFS (Phase II);   OS (Phase II);   Best objective response evaluated via RECIST 1.1 (Phase II);   Toxicity will be determined using the CTCAE version 4.0 criteria (Phase II)
7 Recruiting Study of Etoposide in Treating Patients With Recurrent or Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Etoposide
Outcome Measures: Progression-free survival;   Clinical response rate;   1-year survival rate;   Adverse events;   Quality of Life
8 Recruiting Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Conditions: Recurrent Non-small Cell Lung Cancer;   Stage IIB Non-small Cell Lung Cancer;   Stage IIIA Non-small Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer
Interventions: Radiation: 3-dimensional conformal radiation therapy;   Radiation: intensity-modulated radiation therapy;   Drug: cisplatin;   Drug: Etoposide
Outcome Measure: Maximum tolerated dose of radiotherapy, in terms of number of daily fractions, that can be delivered using 3D-CRT or IMRT with the standard cisplatin/Etoposide regimen
9 Recruiting Bendamustine Hydrochloride, Rituximab, Etoposide, and Carboplatin in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma or Hodgkin Lymphoma
Conditions: Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma
Interventions: Drug: bendamustine hydrochloride;   Drug: carboplatin;   Biological: rituximab;   Drug: Etoposide;   Other: laboratory biomarker analysis
Outcome Measures: Maximally tolerated dose of bendamustine hydrochloride that can be combined with rituximab, carboplatin, and Etoposide chemotherapy in patients with relapsed or refractory lymphoid malignancies;   Safety and toxicity of this regimen;   Preliminary assessment of the efficacy of this regimen;   Ability to proceed to peripheral blood stem cell (PBSC) collection following treatment (impact of this regimen on stem cell reserve)
10 Recruiting Clofarabine, Cyclophosphamide and Etoposide for Minimal Residual Disease Positive Acute Leukemia
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia
Interventions: Drug: Clofarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Biological: allogeneic hematopoietic cell transplantation
Outcome Measures: Number of Patients Unable to Proceed to Transplantation;   Rate of Pre-Transplant Chemotherapy-Induced Aplasia;   Rate of Infectious Complications;   Treatment-Related Mortality After Transplant;   Disease-Free Survival After Transplant;   Rate of Leukemic Relapse After Transplant
11 Recruiting A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Cisplatin in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE)
Condition: Stage IV Small Cell Lung Cancer
Interventions: Drug: OMP-59R5;   Drug: Etoposide;   Drug: Placebo;   Drug: Cisplatin
Outcome Measures: Dose limiting toxicities (DLT) of OMP-59R5 in combination with Etoposide and Cisplatin;   Progression-free survival;   PK of OMP-59R5 when given in combination with Etoposide and Cisplatin.;   Overall survival, 12 month OS and overall response rate;   Number of participants with adverse events as a measure of safety and tolerability
12 Unknown  Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Gemtuzumab ozogamicin;   Drug: Mitoxantrone;   Drug: Etoposide
Outcome Measures: To evaluate the toxicity and response rate of the combination therapy of mitoxantrone, Etoposide and gemtuzumab ozogamicin as second line therapy in patients with acute myeloid leukemia (AML).;   To assess the overall survival in patients with AML treated with the combination of mitoxantrone, Etoposide and gemtuzumab ozogamicin.
13 Recruiting Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Condition: Lung Cancer
Intervention: Drug: LDE225, Etoposide and Cisplatin
Outcome Measures: MTD;   safety, tolerability;   pharmacokinetic profile;   efficacy;   patient-reported outcomes (toxicity-related symptoms)
14 Recruiting Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL
Conditions: Relapsed T-Cell Acute Lymphoblastic Leukemia;   Relapsed T-Cell Lymphoblastic Lymphoma
Interventions: Drug: Nelarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Filgrastim
Outcome Measures: To determine the maximum tolerated doses and dose-limiting toxicities (DLTs) of nelarabine, Etoposide and cyclophosphamide when given in combination to children with T-ALL and bone marrow relapse or T-LL.;   To determine the complete remission rate after 1 and 2 courses of this therapy in children with T-ALL and bone marrow relapse or T-LL.;   To determine the percent of children with T-ALL and 1st BM relapse that have a complete response after therapy on this study and proceed to stem cell transplantation in complete response within 20 weeks of beginning this regimen.;   To determine minimal residual disease (MRD) levels at the end of each course of treatment.;   To evaluate the vitamin B12 pathway and metabolites and the potential association of neurotoxicity following nelarabine therapy with alterations in this pathway.;   To determine, in a preliminary manner, whether patients with relapsed T-ALL/LL have a distinct signaling signature that distinguishes malignant cells from normal thymocytes.;   To evaluate, in a preliminary manner, whether phospho-flow cytometry can be used to predict clinical response to Nelarabine.
15 Recruiting Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Grade III Lymphomatoid Granulomatosis;   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: plerixafor;   Biological: filgrastim;   Drug: Etoposide;   Procedure: leukapheresis
Outcome Measures: Improvement of collection of greater than or equal to 8 x 10^6 CD34+ cells/kg by 25% using plerixafor, Etoposide, and filgrastim;   Improvement of progression-free survival of patients who receive greater than or equal to 8 x 10^6 CD34+ cells/kg following collection with plerixafor, Etoposide, and filgrastim;   Improvement of survival of patients who receive greater than or equal to 8 x 10^6 CD34+ cells/kg by 15% following collection with plerixafor, Etoposide, and filgrastim;   Comparison of neutrophil recovery, platelet recovery, and length of hospital stay between patients receiving greater than or equal to 8 and less than 8 x 10^6 CD34+ cells/kg;   Comparison of overall survival and progression-free survival between patients receiving greater than or equal to 8 and less than 8 x 10^6 CD34+ cells/kg;   Comparison of number of days of apheresis required to achieve goal, transfusion requirements, hospitalization costs, and need for remobilization between patients receiving greater than or equal to 8 and less than 8 x 10^6 CD34+cells/kg;   Correlation of peripheral CD34+ cell count with graft content of CD34+ cells
16 Not yet recruiting Ixazomib, Mitoxantrone Hydrochloride, Etoposide, and Intermediate-Dose Cytarabine in Treating Relapsed or Refractory Acute Myeloid Leukemia
Conditions: Recurrent Adult Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
Interventions: Drug: ixazomib;   Drug: mitoxantrone hydrochloride;   Drug: Etoposide;   Drug: cytarabine
Outcome Measures: DLT assessed using the National Cancer Institute (NCI) Common Toxicity Criteria (CTC) scale version 4.03;   MTD of ixazomib in combination with MEC based on the occurrence of DLT assessed using NCI CTC scale version 4.03;   Recommended Phase 2 dose;   Incidence of non-DLT assessed using NCI CTC scale version 4.03;   Complete response (CR) rate;   Complete remission with incomplete platelet recovery (CRp) rate;   Gene expression profile analysis;   CD74 antigen expression expression analysis
17 Recruiting Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Conditions: Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
Interventions: Drug: carfilzomib;   Biological: rituximab;   Drug: Etoposide;   Drug: carboplatin;   Drug: ifosfamide;   Other: pharmacological study;   Other: laboratory biomarker analysis
Outcome Measures: MTD defined as the dose of carfilzomib added to standard R-ICE chemotherapy which, if exceeded, would put the patient at an undesirable risk of medically unacceptable dose-limiting toxicities (Phase I);   Best overall response rate (PR + CR) (Phase II);   Complete response rate according to the International Working Group Response criteria as reported by the revised Cheson criteria;   Toxicity of the addition of carfilzomib to R-ICE at the MTD, assessed by the CTEP 4ersion 4.0 of the NCI CTCAE;   Overall survival;   Progression-free survival;   Pharmacokinetics (PK)/pharmacodynamics (PD) of carfilzomib and standard R-ICE combination therapy in adult patients with relapsed/refractory diffuse large B-cell lymphoma
18 Recruiting Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors
Condition: Germ Cell Tumors
Interventions: Drug: Paclitaxel;   Drug: Ifosfamide;   Drug: Cisplatin;   Drug: Mesna;   Drug: Bleomycin;   Drug: Etoposide
Outcome Measures: favorable best response rate;   overall best response;   progression-free survival (PFS);   overall survival (OS);   toxicity
19 Recruiting Decitabine Followed By Mitoxantrone Hydrochloride, Etoposide, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Conditions: Adult Acute Basophilic Leukemia;   Adult Acute Eosinophilic Leukemia;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Myeloid Leukemia
Interventions: Drug: decitabine;   Drug: mitoxantrone hydrochloride;   Drug: Etoposide;   Drug: cytarabine;   Other: laboratory biomarker analysis
Outcome Measures: MTD of decitabine defined as the highest dose in which the incidence of dose limiting toxicity (DLT) is < 33%, graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (Phase I);   Remission rate (RR) including CR and CRp (Phase II);   Event-free survival;   Disease-free survival (for patients achieving CR or CRp);   Overall survival
20 Recruiting Carmustine, Etoposide, Cytarabine, Melphalan, and Antithymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Autoimmune Neurologic Disease That Did Not Respond to Previous Therapy
Condition: Autoimmune Disorder
Interventions: Biological: anti-thymocyte globulin;   Drug: carmustine;   Drug: cytarabine;   Drug: Etoposide;   Drug: melphalan;   Drug: prednisone;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: syngeneic bone marrow transplantation;   Other: laboratory biomarker analysis
Outcome Measures: Incidence of grades 4-5 regimen-related toxicity as assessed by the Regimen Related Toxicity Scale;   Transplant-related mortality;   Disease responses as assessed by clinical, laboratory and radiologic evaluation;   Engraftment kinetics;   Efficacy of peripheral blood stem cell mobilization from syngeneic donors and autograft recipients

These studies may lead to new treatments and are adding insight into Etoposid etiology and treatment.

A major focus of Etoposid research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Etoposid